Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Inogen, Inc.NASDAQ: INGN
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$8.42M, compared with -$7.66M a year earlier. Trailing-twelve-month operating income was -$30.97M.
Context
- Operating income amounted to 8.7% of revenue in FY2025, down 4.0 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of -$26.63M (+11.8%) for the fiscal year ending Dec 2026, a slowdown from the +29.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.42M+9.5% QoQ
- Last fiscal yearDec 2025
- -$30.21M+29.0% YoY
- LTMMar 2026
- -$30.97M+8.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.0% | +33.8% | +43.8 pp |
| 1 year | +29.0% | +11.8% | -17.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (30.21M) USD
- Year-over-year change
- +29.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.21M) | +29.0% |
| FY2024 | 2024-12-31 | (42.52M) | +61.1% |
| FY2023 | 2023-12-31 | (109.39M) | -28.3% |
| FY2022 | 2022-12-31 | (85.24M) | -1022.5% |
| FY2021 | 2021-12-31 | 9.24M | — |
Operating Income vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 operating income of -$30.97M is the 3rd highest of the 11 companies compared; the peer median is -$51.59M.
- Its year-over-year change of +8.6% is the 4th highest of 11, against a peer median of -25.2%.
- Operating income amounts to 8.8% of revenue for INGN, versus a peer median of 57.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.84M | -62.0% | — | 6.4% | |
| LTM Mar 2026 | -$18.86M | -30.1% | — | 196.6% | |
| LTM Mar 2026 | -$30.97M | +8.6% | — | 8.8% | |
| LTM Mar 2026 | -$30.98M | -97.4% | — | 57.5% | |
| LTM Mar 2026 | -$35.65M | +28.2% | — | 44.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.1M | -64.4% | — | — |
| LTM Mar 2026 | -$58.09M | +13.5% | — | 19.2% | |
| LTM Dec 2025 | -$60.7M | -7.0% | — | 466.2% | |
| LTM Mar 2026 | -$66.94M | +27.9% | — | 56.9% | |
| LTM Mar 2026 | -$119.82M | -87.7% | — | 82.7% | |
| LTM Mar 2026 | -$120.01M | -20.4% | — | 19419.6% | |
| Peer median (excluding INGN) | -$51.59M | -25.2% | — | 57.5% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 358M | 377.24M | 315.66M | 335.71M | 348.67M |
| Cost of Revenue | 181.52M | 223.71M | 188.96M | 180.96M | 182.78M |
| Gross Profit | 176.48M | 153.53M | 126.7M | 154.74M | 165.89M |
| Gross Margin | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| Research & Development | 16.58M | 21.94M | 20.84M | 21.61M | 19.4M |
| Selling, General & Admin | 150.67M | 164.67M | 182.35M | 175.65M | 165.07M |
| Operating Expenses | 167.24M | 238.78M | 236.09M | 197.26M | 196.1M |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| EBITDA | 30.29M | (9.57M) | (58.34M) | (15.47M) | (2.72M) |
| EBITDA Margin | 8.5% | -2.5% | -18.5% | -4.6% | -0.8% |
| Operating Income | 9.24M | (85.24M) | (109.39M) | (42.52M) | (30.21M) |
| Operating Margin | 2.6% | -22.6% | -34.7% | -12.7% | -8.7% |
| Interest Income | 129K | 2.84M | 6.57M | 5.19M | 2.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (581K) | 1.98M | 7.04M | 6.04M | 6.83M |
| Income Before Tax | 8.66M | (83.27M) | (102.34M) | (36.48M) | (23.38M) |
| Pre-Tax Margin | 2.4% | -22.1% | -32.4% | -10.9% | -6.7% |
| Income Tax Expense | 14.99M | 504K | 105K | (588K) | (632K) |
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Net Margin | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (Basic) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| EPS (Diluted) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| Weighted Avg Shares | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
| Weighted Avg Shares (Diluted) | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.